Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Abstract from Movement Disorders Conference

June 22, 2016 Kerry Rowe

Abstract from Movement Disorders Conference 2016

Post navigation

Prana’s Huntington Disease trial analysis to feature at global movement disorder conference

Prana Alzheimer’s disease data features at world leading conference

Related Posts

Prana Details Data Showing that PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation

July 17, 2013

Prana Biotechnology Investor Presentation

June 27, 2018

Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s

August 4, 2021October 19, 2021

Recent Posts

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065